Menu
Search
|

Menu

Close
X

Cue Biopharma Inc CUE.OQ (NASDAQ Stock Exchange Capital Market)

8.65 USD
-- (--)
As of Mar 21
chart
Previous Close 8.65
Open --
Volume --
3m Avg Volume 31,385
Today’s High --
Today’s Low --
52 Week High 16.96
52 Week Low 4.16
Shares Outstanding (mil) 20.73
Market Capitalization (mil) 179.35
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY18
1
FY17
0
FY16
0
EPS (USD)
FY18
-1.935
FY17
-1.440
FY16
-0.292
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
58.45
Price to Sales (TTM)
vs sector
156.97
9.03
Price to Book (MRQ)
vs sector
5.27
4.61
Price to Cash Flow (TTM)
vs sector
--
40.28
Total Debt to Equity (MRQ)
vs sector
0.00
17.70
LT Debt to Equity (MRQ)
vs sector
0.00
14.01
Return on Investment (TTM)
vs sector
-81.57
12.08
Return on Equity (TTM)
vs sector
-81.57
13.20

EXECUTIVE LEADERSHIP

Daniel Passeri
President, Chief Executive Officer, Since
Salary: --
Bonus: --
Kerri-Ann Millar
Principal Financial Officer, Since 2018
Salary: --
Bonus: --
Rodolfo Chaparro
Executive Vice President - Head of Immunology, Since
Salary: --
Bonus: --
Ronald Seidel
Executive Vice President - Head of Research and Development, Since
Salary: --
Bonus: --
Colin Sandercock
Senior Vice President, General Counsel, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

21 Erie St
CAMBRIDGE   MA   02139-4260

Phone: +1617.9492680

Cue Biopharma Inc is a development-stage immunotherapy company. The Company is focused at developing biologics engineered to selectively modulate disease-relevant T cell subsets to treat cancer and autoimmune disease. Its Immuno-Oncology pipeline includes CUE-100 Framework, and CUE-200 Framework; and autoimmune pipeline includes MHC Class I Program, and MHC Class II Program. The CUE-100 Framework restricts the activity of T cell populations. The CUE-200 Framework enables potent, long-lived anti-tumor T cell responses. The Autoimmune disease therapy protects the healthy cells from immune attack.

SPONSORED STORIES